Tricida Inc

Tricida — Investor Presentation (January 2019)

33 slides from Tricida's investor presentation, Jan 7, 2019

  1. Slide 1: Slowing the Progression of Chronic Kidney Disease Through the Treatment of Metabolic Acidosis

    Slowing the Progression of Chronic Kidney Disease Through the Treatment of Metabolic Acidosis

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Any statements in this presentation that are not statements of historical facts may be deemed to be forward-looking statements. Examples of such statements include our plans, beliefs, intentions, expectations and projections regarding, among other things: anticipated miles

  3. Slide 3: First-in-Class Drug Candidate - TRC101

    First-in-Class Drug Candidate - TRC101 Disease Modifying – Our Goal is to Slow CKD Progression through the Treatment of Metabolic Acidosis Improve How the Patient Feels and Functions – We Believe TRC101 has the Potential to Enhance Health-Related Quality of Life for Patients with Metabolic Acidosis

  4. Slide 4: 2018 Achievements

    2018 Achievements JUNE JUNE OCTOBER DECEMBER Positive Successful Initiated Disease Completed Phase 3 IPO Awareness New HEOR Results Campaign Linking and Payer Metabolic Acidosis Survey and CKD Progression HEOR: Health Economics Outcomes Research. 4

  5. Slide 5: Anticipated 2019 Milestones

    Anticipated 2019 Milestones 1H 2019 Mid-2019 2H 2019 2H 2019 + + = TRCA-301E Stability VALOR-CKD NDA Results Data Enrollment Submission Completion of the Availability of NDA- Completion or near- Submitting under the 40-week safety enabling 12-month completion of enrollment Accelerated Approval exten

  6. Slide 6: Metabolic Acidosis is Caused by Inability of the Kidneys to Excrete Excess Acid

    Metabolic Acidosis is Caused by Inability of the Kidneys to Excrete Excess Acid Kidneys Lose Capacity to Excrete Acid Blood Bicarbonate Levels Fall acid Normal 22 – 29 mEq/L icarbonate Range Blood B Acid is generated Diseased kidneys An increase in acid leads Metabolic 12 – <22 from dietary lose cap

  7. Slide 7: Metabolic Acidosis Poses a Significant Health Risk to ~3 Million Patients with CKD in the US

    Metabolic Acidosis Poses a Significant Health Risk to ~3 Million Patients with CKD in the US ~ 22 Million US Patients with Stage 3 to 5 CKD* ~3 Million with Metabolic Acidosis Potential Consequences Muscle Breakdown & Increased Mortality CKD Progression Bone Disease CKD 3a/b (9-18%) ~2.2 M with Meta

  8. Slide 8: Eleven Studies have Established the Link between Metabolic Acidosis and CKD Progression

    Eleven Studies have Established the Link between Metabolic Acidosis and CKD Progression Seven Prospective Studies Four Retrospective Studies 8

  9. Slide 9: Reduced Risk of ESRD with Normal Blood Bicarbonate: Tangri Kidney Failure Risk Equation

    Reduced Risk of ESRD with Normal Blood Bicarbonate: Tangri Kidney Failure Risk Equation Tangri Metabolic Normal Blood Eight Variables Acidosis* Bicarbonate Age 62 62 Sex M M Relative Reduction in eGFR 26 ml/min 26 ml/min Risk of Progression ACR 250 mg/g 250 mg/g to ESRD with Normal ** Albumin 3.8 g/

  10. Slide 10: Prospective Data Link Treating Metabolic Acidosis to Slowing Kidney Disease Progression

    Prospective Data Provide Evidence of Direct Link Between Treating Metabolic Acidosis and Slowing the Progression of Kidney Disease In a Randomized, Controlled Study, Normalization of … Associated with Slower Decline in Renal Function* Blood Bicarbonate Concentration … /L) 25 ( mEq Normal Metabolic A

  11. Slide 11: Unmet Medical Need for an FDA-Approved Chronic Treatment for Metabolic Acidosis

    Unmet Medical Need for an FDA-Approved Chronic Treatment for Metabolic Acidosis to Slow CKD Progression Oral alkali supplementation is the most common option for managing blood bicarbonate levels as established in academic clinical trials, HOWEVER… Not FDA-Approved Oral alkali supplements are availa

  12. Slide 12: Transforming the Treatment of Patients with CKD and Metabolic Acidosis

    Transforming the Treatment of Patients with CKD and Metabolic Acidosis TRC101 NH2 NH2 NH2 NH2 Designed Does not Appropriate for chronic, oral deliver sodium for all metabolic treatment (once a day or other acidosis patients, sachet) of counterions including mild to severe to the patient those with c

  13. Slide 13: Potential First-in-Class Polymer Designed to Have High Binding Capacity for Removal of Excess Acid

    Potential First-in-Class Polymer Designed to Have High Binding Capacity for the Removal of Excess Acid TRC101 Mechanism of Action Oral Ingestion Acid Binding in GI Tract Cl- Cl- + + + + NH2 NH2 NH3 NH3 NH3 NH3 H+ Cl- Excretion in feces + + + + NH2 NH2 NH3 NH3 NH3 NH3 Cl- Cl- TRC101 is TRC101 binds p

  14. Slide 14: TRC101: High Selectivity for Chloride Ions Derived from Size Exclusion

    TRC101: High Selectivity for Chloride Ions Derived from Built-In Size Exclusion Mechanism GI Anions Ranked by Size Bile Acids The high degree of crosslinking in TRC101 provides a size Fatty Acids exclusion mechanism that TRC101 leads to high selectivity Citrate for binding chloride (the smallest ani

  15. Slide 15: Plan to Submit NDA Under the FDA Accelerated Approval Program in 2H 2019

    Plan to Submit NDA Under the FDA Accelerated Approval Program in 2H 2019 Accelerated Approval Program Requirements Treats a Serious Condition Meaningful Advantage Reasonably Predictive Over Standard of Care Surrogate Endpoint Treatment of metabolic There are no FDA- Increasing blood acidosis may slo

  16. Slide 16: TRCA-301 Phase 3 Trial Design

    TRCA-301 Phase 3 Trial Design Phase 3 Clinical Trial: TRCA-301 (4:3 Randomization) TRC101 QD (n=124) 217 subjects with Placebo QD (n=93) Safety blood bicarbonate of 12 – 20 Screening Follow-up mEq/L, eGFR of 20 – 40 2-week 2-week 2 Fixed dose (6 grams QD) until week 4 with blinded 12 Weeks ml/min/1.

  17. Slide 17: TRCA-301 Trial Met Primary and Secondary Efficacy Endpoints

    TRCA-301 Trial Met Primary and Secondary Efficacy Endpoints 59.2% of TRC101-Treated Subjects Experienced TRC101-Treated Subjects Experienced a Mean Increase from an Increase of ≥4 mEq/L or Reached Normal Baseline in Blood Bicarbonate of 4.5 mEq/L (p<0.0001) Blood Bicarbonate at End of Treatment (p<0

  18. Slide 18: TRCA-301: Exploratory Endpoints Evaluated Potential Physical Function Benefit of TRC101

    TRCA-301: Exploratory Endpoints Evaluated Potential Physical Function Benefit of TRC101 1) Kidney Disease Quality of Life (KDQOL) Physical Function survey ̶ A validated questionnaire designed to assess kidney disease-specific health-related quality of life ̶ Subjects responded to the 10 KDQOL questi

  19. Slide 19: Improvement in KDQOL Physical Function Survey

    Improvement in KDQOL Physical Function Survey TRC101-Treated Patients Reported a Significant Improvement in Physical Function* p(p << 0.00010.0001) TRC101 within group TRC101 within group Baseline = 53.3 points Baseline = 53.3 +6.3 Statistically significant between-group5.2 difference point Between(

  20. Slide 20: Improvement in Repeated Chair Stand Test

    Improvement in Repeated Chair Stand Test TRC101-Treated Patients Experienced a Significant Improvement in Physical Function TRC101TRC101 Baseline =Baseline 17.3 seconds = 17.3 seconds -1.17 Statistically significant between-group1.52 difference:seconds Between1.52 group seconds* improvement in favor

  21. Slide 21: Positive TRCA-301 Safety Results

    Positive TRCA-301 Safety Results • Over 95% of patients in both groups completed the study • SAE incidence low and balanced between the 2 treatment groups – 2 SAEs resulted in death; both occurred in placebo subjects – All SAEs were assessed as not related to study drug • Overall GI tolerability was

  22. Slide 22: TRCA-301E Phase 3 Extension Trial Design

    TRCA-301E Phase 3 Extension Trial Design Phase 3 Nine-Month Extension Trial: TRCA-301E (90% of TRCA-301 subjects elected to participate) TRC101 QD (n=114) Placebo QD (n=82) Subjects from TRCA-301 trial Safety with blood bicarbonate ≥ 12 Follow-up mEq/L who completed Week 12 2-week 40 Weeks Treatment

  23. Slide 23: VALOR-CKD Confirmatory Postmarketing Trial Design

    VALOR-CKD Confirmatory Postmarketing Trial Design Time-to-Event Postmarketing Trial to Evaluate the Efficacy and Safety of TRC101 in Delaying CKD Progression TRC101 QD (n~800) ~1,600 patients with Screening blood bicarbonate of 12 – 20 mEq/L, eGFR of 20 – 40 mL/min/1.73m2 ~4 years ~4 Treatment Place

  24. Slide 24: We Plan to File the TRC101 NDA Under the Accelerated Approval Program in 2H 2019

    We Plan to File the TRC101 NDA Under the Accelerated Approval Program in 2H 2019 TRCA101 Clinical Trials Postmarketing Trial TRCA-101*: Successful 2-week, randomized, double-blind, Initiated enrollment in Q4 2018 placebo-controlled Phase 1/2 trial, 3 doses and 2 dosing regimens of TRC101 or placebo

  25. Slide 25: We Plan to Launch TRC101 in the United States for Patients with CKD and Metabolic Acidosis

    We Plan to Launch TRC101 in the United States for Patients with CKD and Metabolic Acidosis Treated by Nephrologists 25

  26. Slide 26: Positive Payer Feedback From Payers Covering Over Million Lives

    Positive Payer Feedback From 15 Payers Covering Over 200 Million Lives Key Value Drivers  First-in-class • Signaled a formulary ‘must-add’ versus an ‘optional add’ • Recognized unique, meaningful attributes of TRC101 mechanism  Disease modifying of action • Phase 3 results on blood bicarbonate con

  27. Slide 27: Retrospective Study of Pre-Dialysis Patients with CKD Stages 3-5 Using National EMR Dataset

    Retrospective Study of Pre-Dialysis Patients with CKD Stages 3-5 Using a National De-identified Electronic Medical Record Dataset (2007 – 2016) Medical Record Data Medical Claims • Step 1: Observed DD40 renal • Step 3: All-cause costs evaluated for two years in outcomes for patients with Modeled con

  28. Slide 28: Improvement in Blood Bicarbonate Associated with Potential Cost and Renal Outcome Benefits

    Improvement in Blood Bicarbonate by ~ 4 mEq/L was Associated with Potential for Measurable Cost and Renal Outcome Benefits in Commercial Patients Observed in patients with Estimated benefit of metabolic acidosis in the 4 mEq/L increase in EMR data study blood bicarbonate (N = 5,178) (N = 5,178) N %

  29. Slide 29: Significant US Market Opportunity for TRC101

    Significant US Market Opportunity for TRC101* Increased awareness drives higher metabolic 3,000,000 acidosis diagnosis and treatment CKD patients with metabolic acidosis Expansion beyond nephrologists 1,100,000 provides additional opportunity Diagnosed patients 600,000 Sodium bicarbonate (baking sod

  30. Slide 30: Tricida is Raising Awareness about Metabolic Acidosis and CKD Progression

    Tricida is Raising Awareness about Metabolic Acidosis and CKD Progression Major Presence at ASN Kidney Week 2018 New Educational Neph+ App Videos and Designed By MetabolicAcidosis and For Insights.com Nephrologists Website 30

  31. Slide 31: Comprehensive Worldwide IP Strategy

    Comprehensive Worldwide IP Strategy United States Europe Rest of World • Issued composition of • Issued European • Corresponding matter and method of patents applications in other treatment patents commercially significant • Several pending countries • Several pending applications applications Paten

  32. Slide 32: Financial Highlights

    Financial Highlights • $260.5 million cash, cash equivalents and short term investments at September 30, 2018 • $40 million drawn down on a $100 million Hercules term loan at December 31, 2018 – $25 million and $15 million drawn down in February and December 2018, respectively – Additional draw down

  33. Slide 33: Thank You

    THANK YOU [RICIDA

Tricida — Investor Presentation (January 2019) on 6ix